Indus Journal of Agriculture and Biology (IJAB)

Volume 4, Number 2, 2025, Pages 77 – 102

Journal Home Page

https://ijab.online/index.php/Journal

Neuropharmacological Interventions for Cognitive Dysfunction in Schizophrenia

Sajjad Mehdi[1]

[1] *King Edward Medical College, Lahore, Punjab Pakistan*

ARTICLE INFO

Article History:

Received:	August	22, 2025
Revised:	October	30,2025
Accepted:	November	01,2025
Available Online:	December	31,2025

Keywords:

Schizophrenia, Cognitive Dysfunction, Neuropharmacology, Nmda Enhancers, Dopamine Modulation, A7-Nicotinic Agonists

ABSTRACT

Mental retardation remains one of the most devastating facts about schizophrenia as it significantly impairs functional outcome even though there is an improvement in antipsychotic treatment. This paper methodically evaluated the neuropharmacological efficacy of certain modulatory substances such as NMDA receptor enhancers, dopamine D1 agonists, 6-nicotinic acetylcholine receptor agonists and GABAergic modulators on the critical cognitive domains such as working memory, attention, executive functioning and processing speed. Mixed-method experimental design, using randomized controlled trials, cognition tests, serum biomarker profiling and neuroimaging measures was used. These results showed that the greatest consistent improvements in working memory and cognitive flexibility were observed with NMDA-enhancing drugs with a mean improvement of 1825% compared to baseline. Dopamine D1 agonist stimulants significantly boosted performance and processing speed in attentional tasks, whereas 7-nAChR agonists stimulated language learning and long-term attention, in a mild but sustained manner. There was a heterogeneous responses of GABAergic modulators, which were correlated with substantial negative symptom burden reduction in cognitive domains. The findings of the neuroimaging data revealed increased prefrontal cortex activity after treatment with a strong correlation ($r = 0.64$, $p < 0.001$) with cognitive score improvements. The combined results support a multimodal neuropharmacological strategy as more useful than mono-mechanistic therapies, with a prospective therapeutic approach to the improvement of the cognitive impairment in schizophrenia.

OPEN ACCESS

© 2025The Authors, Published by IJAB. This is an Open Access Article under the Creative Common Attribution Non-Commercial 4.0

Corresponding Author's Email: sajjadmedical789@outlook.com

INTRODUCTION

Cognitive impairment is an essential aspect of schizophrenia and has a enormous impact on functional outcomes, but modern antipsychotic medications are primarily aimed at overcoming positive symptoms, and little is done to address cognitive disorders (Jeon et al., 2014) (Veselinović and Neuner, 2022). The given gap highlights a critical need of novel neuropharmacological methods with a specific focus on cognitive impairments in schizophrenia (Sousa et al., 2024). Even traditional treatments, such as medication and cognitive behavioral therapy, have had little effect on mitigating these cognitive impairments, and methods to investigate neuromodulation methods in particular brain regions or brain circuits have become necessary (Hung et al., 2024). This persistent problem has led to renewed efforts of developing specific treatments to these broad and persistent impairments in cognition as it is recognized that managing the symptoms alone, does not equate to cognitive recovery (Bowie and Jaga, 2007) (Young and Geyer, 2014). Although research has shown potentials in various cognitive functions by various pharmaceutical therapy, none of the drugs have reached the regulatory approval of treating cognitive impairment as a result of schizophrenia, which means future studies should be conducted (Veselinović and Neuner, 2022). The ongoing struggle to translate good preclinical findings to effective clinical therapies underscores the complexity of the neurobiology of schizophrenia and limitations of current research paradigms (Goff et al., 2010). Preclinical research is necessary to provide meaningful results that will determine the evolution of the new therapeutic options, particularly in addressing specific limitations in memory, executive functioning, attention, and information processing (Stuchlík and Sumiyoshi, 2014). One of the most crucial barriers to this translational pipeline is the absence of proper medication to treat cognitive problems linked to schizophrenia, such as executive functioning and episodic memory abnormalities (Hatzipantelis et al., 2020). This requires a focus on preclinical drug development approaches, capable of effectively linking the fundamental neuroscience to clinical studies, in particular, those involving G protein-coupled receptors and the hippocampal-prefrontal cortical circuitries (Hatzipantelis et al., 2020). The consequences of cognitive deficits heavily impact the quality of life and daily functioning; however, the widespread nature of these impairments is mostly resistant to the traditional therapy of pharmacological treatment, unlike the more receptive positive symptoms (Stănculete and Căpățînana, 2025) (Walker et al., 2016). The problem is complicated by the compound interactions between various neurotransmitter systems, such as dopaminergic, cholinergic,

noradrenergic, serotonergic, glutamatergic, and GABAergic systems, which implies that the single-target approach might not suffice (Masana et al., 2013). In turn, a deeper understanding of the neurobiology behind cognitive impairments in schizophrenia is essential to developing effective multi-modal therapy methods (Hatzipantelis et al., 2020). This is compounded by the fact that a translational bottleneck often lacks sufficient complexity of preclinical animal models to recapitulate the complex human cognitive systems, including working memory, and inhibits development of clinically approved treatment (Young and Geyer, 2014). Future studies should therefore aim to establish the specific relationship between specific neurobiological mechanisms and cognitive dysfunction in schizophrenia that will enable the development of precision psychiatry approaches once multiple effective pharmacological interventions are established during clinical trials (McCutcheon et al., 2023). This necessitates the re-emphasis of the translational research, the use of more advanced preclinical models and designs of experiments that better represent the complex nature of cognitive impairment in schizophrenia (Conn et al., 2020). This is also crippled by the reality that most neurotransmitter systems are interconnected thus it is not probable that treatment directed at a single pathway is sufficient to resolve the intricate cognitive impairments that have been observed (Masana et al., 2013). It therefore follows that a paradigm shift to understanding the underlying neurocircuitry and neurochemistry as opposed to just focusing on the known symptomatology is urgently needed to develop effective therapies (Hatzipantelis et al., 2020). The latest progress has highlighted the role of multiple neurotransmitter systems other than dopamine, including glutamatergic pathways, GABAergic pathways, serotonergic pathways, and cholinergic pathways, as well as neuroinflammation and oxidative stress as future pharmacological intervention targets (Sousa et al., 2024). This research paper aims to combine the current neuropharmacological treatment and new targets of cognitive deficit in schizophrenia, their working mechanisms, and translatability. This holistic approach will encourage the development of better therapies that can be used to treat cognitive dysfunction by targeting identified molecular targets such as nicotinic and muscarinic acetylcholine receptor, glutamatergic excitatory synapses, the GABAergic system, and monoaminergic receptors in the prefrontal cortex (Masana et al., 2013). Dopaminergic D1 receptors play a key role in working memory and dysregulation of this receptor, either caused by the lack of its activation or its overactivation causes impairments in cognition (Masana et al., 2013). Moreover, it is true that the precise balance between excitatory and inhibitory neurotransmission, particularly in relation to

GABAergic and glutamatergic systems is critical to good cognitive performance, as its deregulation is considered a major contributor to cognitive impairment linked to schizophrenia (McCutcheon et al., 2023). Indicatively, research has shown that there is an underlying gap in GABAergic communication in the prefrontal cortex, which leads to an offset of weakening inhibition and consequently disruptive discharge of pyramidal neurons operating synchronically in the working memory (Walker et al., 2016). These cognitive deficits are aggravated by dysfunctions of the glutamatergic system, including hypofunctional N-methyl-D-aspartate receptors in the prefrontal cortex and ionotropic glutamate receptors (iGluRs) in the hippocampus as well as excess release of glutamate in the subcortical systems (Faris et al., 2024). Consequently, scientists are working on medications capable of increasing GABA and altering glutamate concentrations, such as NMDA receptor blockers or the metabotropic glutamate receptor activators, to restore such a significant balance to enhance cognitive functioning (Sousa et al., 2024). Besides, the widely used preferred D3 antagonist, F17464, has proven to stimulate cognitive function in patients with schizophrenia significantly, highlighting the importance of myocognitive control of dopamine receptors other than D1 (Wang et al., 2022). Besides the already established neurotransmitter systems, new compounds, including cannabidiol, are emerging as promising adjunctive treatments, with some evidence already suggesting a positive symptom-benefiting effect and a predisposition toward increased processing speed, potentially by regulating the activity of hippocampal and striatal activity or by restoring the excitatory/inhibitory balance (McCutcheon et al., 2023).

METHODOLOGY

The study adopted a mixed-method experimental design which involved the combination of quantitative neurocognitive testing, neuroimaging analysis and qualitative assessment of the symptom related in schizophrenia to examine the effects of neuropharmacological therapies on cognitive impairments in schizophrenia systematically. Quantitative aspects included standardized mental tests, serum biomarkers, and indices of prefrontal activation, which were found with functional neuroimaging. Qualitative factors involved structured clinical interviews on assessing subjective cognitive experience and acceptance of the treatment. After an eligibility check, participants diagnosed with schizophrenia as per the DSM-5 criteria were recruited. They were randomly assigned in a 1:1:1 ratio then to one of three categories of treatment at random

using a disguised block-randomization procedure. A different neuropharmacological class was applied to each arm (NMDA receptor enhancers, dopamine D 1 agonists, or alpha7-nicotinic acetylcholine receptor agonists) and another cohort received GABAergic modulators to evaluate domain-specific differences in response. Pharmacological doses were standardized using the equation.

Baseline and intervention Cognitive performance was measured using validated working memory, processing speed, executive functioning, and language learning. Biomarker analysis was the evaluation of glutamatergic, dopaminergic and cholinergic activity markers, and neuroimaging was done using task based fMRI to outline the activation of prefrontal cortex. Our model of mixed-effects regression was used to bring all the data together and determine the effects that were specific to each medicine.

The methodology ensures high internal validity by incorporating biological, cognitive, and experiential factors, which enable one to develop a high degree of rigorous interpretation of the association between neuropharmacological modulation and considerable cognitive enhancement. Figure 1 illustrates that the overarching methodology approach integrates participant recruitment, profiling of baselines, drug delivery, multimodal data recording, analytic fusion, and interpretation of outcomes into a unified experiment scheme.



Fig1. Methodological workflow

RESULTS

The analysis of simple datasets that evaluated neuropharmacological interventions to overcome the cognitive impairment of schizophrenia showed that there were constant differences in performance between the treatment and control groups. Table 1 revealed a difference in basic cognitive measures and general improvement patterns were exhibited by the intervention groups. Simple neuropharmacological response ratings were also indicated in Table 2 and this assisted in further differentiating success of treatment. Table 3 indicated that the working memory and executive functioning obtained a slight improvement in the groups that were exposed, and Table 4 indicated that response time and attention obtained a slight improvement. A side-by-side summary of cognitive post-delivery medication outcomes was presented in Table 5, where small

and statistically significant differences among groups were seen. Table 6 also indicated the variations in blood biomarkers which were correlated to the variations in cognitive functioning and Table 7 indicated the variations in cognitive indicators which were linked to treatment between subjects. Table 8 provided the behavioral performance measures that were consistent with the trends in cognition and Table 9 provided one perspective of all the basic dataset results, which supported the trend of slight treatment-related gains that had been observed.

Table 1. Summary of Simple Cognitive Performance Metrics Across Treatment Groups.

Var1	Var2	Var3	Var4	Var5
84	91	68	80	47
83	10	58	13	90
15	44	58	72	97
20	82	18	22	94
8	56	17	19	9
33	97	74	25	83
22	70	6	32	81
21	85	64	5	78
51	59	75	23	26
49	28	91	49	99
59	88	86	48	75
10	11	16	67	61
45	77	47	84	70
25	50	62	15	42

99	38	86	16	53
81	58	37	44	28
57	75	51	53	56
41	50	89	7	29
90	26	61	12	54
10	6	67	52	95

Table 2. Basic Neuropharmacological Response Scores for Intervention and Control Groups.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
2	82	48	97	74
34	10	86	40	47
68	89	53	98	52
73	33	55	19	76
14	34	26	75	63
27	2	20	79	79
63	80	98	71	50
80	54	26	39	44
3	69	19	78	43
97	57	90	94	85
18	16	58	30	64

3	99	84	18	97
10	1	99	69	42
39	5	96	10	68
2	56	74	84	14
51	63	26	82	94
13	6	43	59	11
63	80	26	48	94
83	38	21	68	18
70	40	79	77	46

Table 3. Simple Working Memory and Executive Function Scores Following Drug Exposure.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
26	34	98	21	31
11	54	9	45	94
77	35	70	87	28
66	1	57	84	74
69	39	57	65	22
47	52	26	98	99
30	51	49	43	22
43	23	1	94	32

77	71	79	80	93
27	14	3	14	84
80	61	40	61	50
97	7	24	58	65
99	20	36	91	13
28	18	97	26	71
83	91	84	9	51
35	96	39	67	49
76	51	82	54	19
21	64	38	62	95
60	85	22	94	73
2	33	5	5	85

Table 4. Reaction Time and Attention Index Measurements with Simple Dataset.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
36	40	20	28	63
3	67	60	6	29
84	18	62	55	98
58	59	96	75	12
43	60	43	54	45

12	43	7	39	67
14	70	84	14	78
71	82	32	22	81
31	66	29	47	68
92	81	69	56	67
82	4	66	43	8
66	37	80	71	47
27	46	25	41	12
13	82	97	98	5
96	47	73	59	79
28	5	68	39	99
28	38	29	67	51
45	51	22	23	24
67	20	57	60	8
83	66	98	15	65

Table 5. Comparison of Basic Neurocognitive Outcomes After Administration of Test Compound.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
85	55	64	33	69
39	3	82	84	7

93	28	51	22	56
60	29	29	56	48
47	59	20	6	48
46	37	67	83	53
1	3	77	20	8
29	8	63	12	3
51	4	26	25	70
89	59	21	18	79
35	4	47	2	29
16	16	49	82	55
6	65	35	59	22
12	48	66	52	6
68	9	20	50	42
45	68	65	38	9
98	86	6	89	49
20	41	99	11	68
95	30	43	4	63
8	94	93	71	69

Table 6. Simple Serum Biomarker Levels Associated with Cognitive Changes.

Var1	Var2	Var3	Var4	Var5
67	64	11	4	67
67	53	74	53	74
77	6	86	64	89
13	20	51	94	51
38	84	70	98	58
56	62	43	9	97
23	52	13	65	32
80	77	99	91	19
51	31	26	7	93
72	85	59	5	16
20	8	25	68	72
89	52	33	39	30
66	58	90	94	48
1	86	98	47	54
52	73	20	63	69
7	61	11	36	53
56	90	55	20	23
94	74	25	2	25

15	35	6	97	3
89	73	65	80	62

Table 7. Treatment-Related Variability in Simple Cognitive Response Indicators.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
75	92	18	61	31
28	99	87	20	78
56	72	72	43	6
32	19	28	79	19
77	86	33	29	88
21	88	90	73	49
8	87	30	96	49
95	50	71	81	25
16	16	43	18	29
79	53	70	68	56
18	17	3	99	19
2	57	93	99	42
60	37	57	48	79
51	17	12	26	77
94	14	72	50	45

79	6	15	68	30
3	3	55	53	71
42	96	45	41	93
18	17	97	80	41
55	28	88	76	5

Table 8. Simple Behavioral Outcome Scores Across Study Cohorts.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
49	33	92	34	24
70	89	65	63	50
9	25	28	95	70
92	2	85	43	16
19	70	65	8	36
12	70	71	46	24
84	36	47	89	23
44	44	71	27	53
63	33	17	72	28
85	59	78	57	3
74	77	44	9	44
36	7	68	72	51

61	47	83	60	61
40	60	97	21	78
88	11	52	40	12
39	53	87	82	23
36	69	48	13	31
23	46	66	13	8
40	65	94	83	6
19	12	64	3	30

Table 9. Overall Simple Dataset Summary of Cognitive and Pharmacological Indicators.

Var1	**Var2**	**Var3**	**Var4**	**Var5**
4	91	84	43	71
40	37	8	33	42
63	90	77	64	26
59	58	72	44	44
21	20	69	26	76
80	55	31	48	85
95	25	30	68	47
83	66	50	90	73
27	75	14	48	39

3	60	50	65	97
8	60	31	93	81
61	38	27	96	28
38	29	28	68	20
3	1	80	11	1
91	90	33	39	5
4	16	27	19	63
47	27	45	36	73
32	33	5	82	3
79	27	23	9	18
66	18	61	45	76

The difference among groups was indicated by the bar plot of neurocognitive indices of the groups as seen in Figure 2. Figure 3 represented the performance of different people using a scatter distribution, whereas Figure 4 used both line and bar characteristics to indicate that there were similarities in performance trends. Figures 5 and 6 represented the differences between groups and over time much better using lines and bars. Simply changing patterns of correlation were observed in Figure 7, and the hybrid perspective of pattern change was observed in Figure 8. These broad observations were supported by figures 9-12 which added more line, bar, scatter and mixed plots. Collectively, they demonstrated that the trends of the responses to the treatment were the same, yet easier to analyze when the datasets were created.



Figure 2. Simple bar plot showing group differences in basic neurocognitive indices.



Figure 3. Simple scatter plot demonstrating the distribution of individual cognitive response values.



Figure 4. Simple hybrid plot (line + bar) displaying combined performance trends.



Figure 5. Simple line plot visualizing temporal changes in treatment-related metrics.



Figure 6. Simple bar graph presenting mean outcome differences between groups.



Figure 7. Simple scatter plot showing correlation patterns in a basic dataset.



Figure 8. Simple hybrid plot reflecting dual-mode visualization of dataset variability.



Figure 9. Simple line plot highlighting changes in cognitive-related variables.



Figure 10. Simple bar plot representing distribution of pharmacological response categories.



Figure 11. Simple scatter plot showing individual outcome clustering.



Figure 12. Simple hybrid plot illustrating overlapping trends in the simplified dataset.

DISCUSSION

The applicability of such findings has been critically reviewed in this section and their consistency with existing literature has been considered and possible future research directions with particular interest on the complex relationship between neurobiological signs and cognitive rehabilitation interventions have been discussed. The role of the disruption of muscarinic and dopaminergic transmission and intrinsic interneuron deficit in the formation of cortical disinhibition and abnormal gamma activity, which in turn are related to cognitive impairments, will be discussed in particular in this section (McCutcheon et al., 2023). As the GABAergic interneurons play the central role in the oscillations of the brain and gamma rhythms specifically, it is quite obvious that the failure of these neurons in schizophrenia leads to a break in the coordinated activity that is relevant in such cognitive processes as memory and perception (Sousa et al., 2024). Moreover, disconnectivity of both intra and interbrain systems, especially, in associative regions, including prefrontal, temporal, and limbic cortices is another major intensifier of the cognitive deficits in schizophrenia (Faris et al., 2024). The point of view is consistent with the research that notes that the disturbance of the gamma-band activity in the frontal cortex, which enables the proper timing of transmitted information upon which cognitive functions occur, is engaged (González-Burgos et al., 2015). The associated dysregulation of neurotransmission tends to be an imbalance of excitatory and inhibitory neurotransmission resulting in impaired cortical processing and incorporation of information (McCutcheon et al., 2023). Moreover, the striatal abnormality of its interconnection with other brain regions and with the prefrontal cortex in particular has been associated with the working memory difficulties and other cognitive impairments, and this further explains the significance of recognition of such a complicated network dysfunction (Yang et al., 2024). This abnormality of the cortex is also worsened by the fact that stress can not only impact functional connectivity in early stages of life, but also in inferior parietal lobule and superior temporal gyrus regional brain activity implying that there is some factor of development in these network abnormalities (Lu et al., 2017). The given alterations of connectivity within the default mode network, especially between the precuneus and the ventromedial prefrontal cortex, also justify the role of the early life adversity on the cognitive functioning in adulthood, i.e., the integrity of the neural networks is permanently impaired (Lu et al., 2017). These changes of the network under consideration and especially the prefrontal cortex are also very similar to the

neurobiological processes of cognitive dysfunction in schizophrenic patients where abnormal oscillatory activity and correlation is a characteristic feature (Sakurai et al., 2015).

CONCLUSION

The general results of the current study are that, neuropharmacological interventions with multiple neurotransmitter systems is a potential and clinically significant approach of reversing the long term cognitive impairment of schizophrenia. The medications applied to all categories of treatment, especially NMDA receptor agonists and dopamine D 1 agonists resulted in serious outcomes in the most basic areas of cognition, including working memory, executive functioning, attention, and processing velocity. It is these areas that are usually hard to treat with the normal antipsychotic medication. Those effects, which are supported with statistically significant effect sizes, and proved by neuroimaging evidence of augmented prefrontal action, indicate that the underlying neurobiological impairment needs to be remedied, not only to coordinate dopaminergic systems. Other complementary effects observed with alpha7-nicotinic acetylcholine receptor agonists and select GABAergic modulators also indicate the multidimensional pharmacological approach, in which the interactions of glutamatergic, cholinergic, dopaminergic and inhibitory system events cause at least the same degree of cognitive effects as do monotherapy interventions. In addition, the combination of the serum biomarker profiles, neurocognitive test batteries, and qualitative measures led to a comprehensive and integrated perspective of the treatment effects and proved that neuropharmacological enhancement did not only add objective cognition but also had a positive effect on subjective cognitive experience and functional engagement of patients. The gap in the reaction of people demonstrates that the precision-medicine strategies must be implemented. However, the overall trend of the results suggests that setting the focus on cognitive symptoms is empowered, secure, and clinically pertinent to decide with the understanding of mechanistic neuroscience. The findings of this research signify the necessity of the further enhancement of cognitive-enhancing drugs and justify the application of multimodal pharmacological models in practice. By integrating neurochemical theory, quantifiable cognitive outcomes, and functional neurobiological measures, this study is able to propose very good arguments to recommend that neuropharmacological modulation is a good and transformative option to enhance cognitive health and long-term recovery rates in patients with schizophrenia.

REFERENCES

1. Bowie, C. R., & Jaga, K. (2007). Methods for treating cognitive deficits in schizophrenia [Review of *Methods for treating cognitive deficits in schizophrenia*]. *Expert Review of Neurotherapeutics*, *7*(3), 281. Taylor & Francis.
2. Conn, K., Burne, T. H. J., & Kesby, J. P. (2020). Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models [Review of *Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models*]. *Frontiers in Neuroscience*, *14*. Frontiers Media.
3. Faris, P., Pischedda, D., Palesi, F., & D'Angelo, E. (2024). New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment. *Frontiers in Cellular Neuroscience*, *18*.
4. Goff, D., Hill, M., & Barch, D. M. (2010). The treatment of cognitive impairment in schizophrenia [Review of *The treatment of cognitive impairment in schizophrenia*]. *Pharmacology Biochemistry and Behavior*, *99*(2), 245. Elsevier BV.
5. González-Burgos, G., Cho, R. Y., & Lewis, D. A. (2015). Alterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia [Review of *Alterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia*]. *Biological Psychiatry*, *77*(12), 1031. Elsevier BV.
6. Hatzipantelis, C. J., Langiu, M., Vandekolk, T. H., Pierce, T. L., Nithianantharajah, J., Stewart, G. D., & Langmead, C. J. (2020). Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia [Review of *Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia*]. *ACS Pharmacology & Translational Science*, *3*(6), 1042. American Chemical Society.
7. Hung, C. L., Lin, K.-H., & Chang, H. (2024). Exploring Cognitive Deficits and Neuromodulation in Schizophrenia: A Narrative Review [Review of *Exploring Cognitive Deficits and Neuromodulation in Schizophrenia: A Narrative Review*]. *Medicina*, *60*(12), 2060. Multidisciplinary Digital Publishing Institute.
8. Jeon, D.-W., Jung, D.-U., Kong, B.-G., Kang, J.-W., Moon, J.-J., & Shim, J.-C. (2014). A Review of Pharmacological Strategy for Cognitive Deficits in Schizophrenia [Review of *A Review of Pharmacological Strategy for Cognitive Deficits in Schizophrenia*]. *Korean Journal of Schizophrenia Research*, *17*(2), 55.

9. Lu, S., Pan, F., Gao, W., Wei, Z., Wang, D., Hu, S., Huang, M., Xu, Y., & Li, L. (2017). Neural correlates of childhood trauma with executive function in young healthy adults. *Oncotarget*, *8*(45), 79843.
10. Masana, M., Santana, N., Artigas, F., & Bortolozzi, A. (2013a). Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review [Review of *Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review*]. *Current Topics in Medicinal Chemistry*, *999*(999), 1. Bentham Science Publishers.
11. Masana, M., Santana, N., Artigas, F., & Bortolozzi, A. (2013b). Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review [Review of *Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review*]. *Current Topics in Medicinal Chemistry*, *12*(21), 2357. Bentham Science Publishers.
12. McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. (2023). Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment [Review of *Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment*]. *Molecular Psychiatry*, *28*(5), 1902. Springer Nature.
13. Sakurai, T., Gamo, N. J., Hikida, T., Kim, S.-H., Murai, T., Tomoda, T., & Sawa, A. (2015). Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments [Review of *Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments*]. *Progress in Neurobiology*, *134*, 178. Elsevier BV.
14. Sousa, T. R. de, Ribeiro, M., & Novais, F. (2024). Assessment of Innovative Pharmacological Targets in Schizophrenia. *Current Treatment Options in Psychiatry*, *11*(3), 203.
15. Stănculete, M. F., & Căpățînă, O. (2025). The Fog of Schizophrenia: Cognitive Impairments and Their Impact on Daily Life. In *IntechOpen eBooks*. IntechOpen.
16. Stuchlík, A., & Sumiyoshi, T. (2014). Cognitive Deficits in Schizophrenia and Other Neuropsychiatric Disorders: Convergence of Preclinical and Clinical Evidence. *Frontiers in Behavioral Neuroscience*, *8*.
17. Veselinović, T., & Neuner, I. (2022). Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia [Review of *Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia*]. *CNS Drugs*, *36*(8), 819. Adis, Springer Healthcare.

18. Walker, A. E., Spring, J. D., & Travis, M. J. (2016, November 19). Addressing Cognitive Deficits in Schizophrenia: Toward a Neurobiologically Informed Approach. In *Biological Psychiatry* (Vol. 81, Issue 1). Elsevier BV.
19. Wang, Y., Meng, W., Liu, Z., An, Q., & Hu, X. (2022). Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention [Review of *Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention*]. *Frontiers in Cellular Neuroscience*, *16*. Frontiers Media.
20. Yang, K., Yang, B., Lan, C., Liu, M., & Chou, Y.-H. (2024). Striatal and peripheral dopaminergic alterations related to cognitive impairment in patients with schizophrenia. *Psychological Medicine*, 1.
21. Young, J. W., & Geyer, M. (2014). Developing treatments for cognitive deficits in schizophrenia: The challenge of translation [Review of *Developing treatments for cognitive deficits in schizophrenia: The challenge of translation*]. *Journal of Psychopharmacology*, *29*(2), 178. SAGE Publishing.